A Phase II Study of OSI 774 (IND Number 63383) in Combination With Celecoxib (Celebrex, Pharmacia) as Second-Line Therapy in Advanced Non-Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2015
At a glance
- Drugs Celecoxib (Primary) ; Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 21 Feb 2008 Status changed from in progress to completed.
- 04 Sep 2005 New trial record.